<DOC>
	<DOCNO>NCT02738502</DOCNO>
	<brief_summary>The overall goal study feasibility darunavir/ritonavir ( DRV/r ) monotherapy treatment simplification ( switch ) pretreated pregnant woman , associate neonatal prophylaxis nevirapine , constitute PMTCT strategy without Nucleoside Reverse Transcriptase Inhibitor ( NRTIs ) .</brief_summary>
	<brief_title>Prevention Perinatal Transmission HIV-1 Without Nucleoside Reverse Transcriptase Inhibitors</brief_title>
	<detailed_description>120 participant enrol switch darunavir monotherapy early pregnancy ( 16 week amenorrhea ) order reduce exposure antiretroviral nucleos ( ) ide analogue . The study treatment pregnancy : darunavir 600 mg + ritonavir 100 mg 2 time 24 ( DRV/r ) monotherapy This regimen start check tolerance DRV/r 600 mg/100 mg twice daily ( recommended dosage pregnancy French national recommendation ) replace whatever prior antiretrovirals ( ARVs ) use , maintain NRTI backbone 2 week . Woman already receive triple drug combination DRV/r proceed directly treatment simplification . If clinical tolerance DRV/r satisfactory 2 week , nucleos ( ) ides stopped . In case intolerance , treatment determine investigator follow-up patient continue . No zidovudine administer delivery case virological control , accord French Guidelines ( Morlat Report 2015 ) . After delivery , choice maternal antiretrovial therapy ( ART ) leave discretion clinician patient . The mother follow monthly delivery last visit plane W4-W6 postpartum . Virological efficacy safety assess monthly . In neonate , prophylactic treatment , nevirapine oral solution , administrate soon possible first 12 hour life 14 day , day daily dose 15 mg birthweight ≥ 2.5 kg ; 10 mg birthweight ≥ 2 kg &lt; 2.5 kg 2 mg / kg birthweight &lt; 2 kg ( WHO Guidelines 2013 - French Guidelines , `` Morlat Report '' 2015 ) . Clinical virological monitoring perform Day 3 , Day 15 case hospitalization , M1 , M3 M6 . Statistical Methods The analysis primary endpoint proportion virological success ( VL &lt; 50 copies/mL delivery among woman remain DRV/r ) . All change antiretroviral therapy VL ≥ 50 copies/ml consider failure . Women change antiretroviral therapy reason remove denominator . Analysis treatment change , tolerance mother child factor associate virological failure do estimating percentage ( categorical variable ) , average median ( continuous variable ) intervals 95 % confidence , overall compare group virological success failure per protocol ( primary endpoint ) intention treat ( secondary endpoint ) . The evolution parameter measure child birth , 1 , 3 , 6 , month explore use non-parametric curve compare group repeat data take account nonlinearity development . No interim analysis plan .</detailed_description>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Darunavir</mesh_term>
	<mesh_term>Reverse Transcriptase Inhibitors</mesh_term>
	<criteria>Pregnant woman , 15 week gestational age screen Documented Human Immunodeficiency Virus ( HIV ) HIV1 infection ( serology and/or plasma HIV RNA viral load ) Current treatment least two ARVs Virological suppression least 12 month , define PVL &lt; 50 copy / mL . A blip ( transiently ≥ 50 &lt; 400 copies/mL ) consider exclusion criterion , follow 2 successive control CV &lt; 50 least one month enrollment Plasma viral load &lt; 50 copies/mL preinclusion CD4 &gt; 250 cells/mm3 history CD4 count nadir &gt; 200/mm3 Informed write consent Health care coverage Inclusion criterion child : Mother enrol trial Informed write consent parent legal guardian Infection HIV2 History treatment failure and/or resistance Protease Inhibitor ( PI ) Known intolerance darunavir ritonavir Hepatitis B Virus ( HBV ) coinfection ( HBs Agpositive and/or detectable HBV DNA ) therapy analog ( tenofovir , emtricitabine , lamivudine ) Known resistance maternal viral strain darunavir nevirapine Intended absence ( travel abroad , move ... ) Persons guardianship deprive liberty judicial administrative decision Exclusion criterion child : Refusal parent ( ) legal guardian ( )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>HIV</keyword>
	<keyword>prevention mother-to-child transmission</keyword>
	<keyword>Ritonavir boost darunavir monotherapy</keyword>
</DOC>